Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy

Area of Science:

• Cardiology
• Cardiac Surgery
• Electrophysiology

Background:

• Left ventricular outflow tract (LVOT) obstruction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM).
• LVOT obstruction contributes to heart failure progression and is a significant risk factor for sudden cardiac death (SCD).
• Medical management is often insufficient for symptomatic patients, necessitating interventional approaches.

Purpose of the Study:

• To evaluate the efficacy of septal reduction therapies in managing LVOT obstruction in HOCM.
• To assess the impact of these treatments on patient symptoms, survival, and risk of sudden cardiac death.
• To highlight the importance of procedural expertise in achieving optimal outcomes.

Main Methods:

• Review of septal reduction treatments including surgical myectomy and alcohol septal ablation for HOCM.
• Analysis of outcomes related to symptom improvement, LVOT gradient reduction, and survival rates.
• Examination of the effect on ventricular tachyarrhythmias and sudden cardiac death risk stratification.

Main Results:

• Septal reduction therapies effectively reduce LVOT gradients and improve symptoms in HOCM patients.
• These interventions are associated with improved survival, comparable to the general population.
• Sudden cardiac death risk appears reduced post-treatment, suggesting LVOT obstruction's role in ventricular arrhythmias.

Conclusions:

• Septal reduction therapy is a valuable treatment for drug-refractory HOCM with LVOT obstruction.
• Effective treatment improves the SCD risk profile, even in patients with pre-existing implantable cardioverter-defibrillators (ICDs).
• Optimal outcomes are achieved in high-volume centers, emphasizing the need for specialized expertise.